Ownership Capital B.V. Purchases 613,817 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ownership Capital B.V. increased its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 21.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,489,915 shares of the medical research company's stock after purchasing an additional 613,817 shares during the period. Edwards Lifesciences accounts for about 5.9% of Ownership Capital B.V.'s investment portfolio, making the stock its 5th biggest holding. Ownership Capital B.V. owned about 0.58% of Edwards Lifesciences worth $266,106,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of EW. Martin Capital Advisors LLP lifted its holdings in Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company's stock worth $1,944,000 after acquiring an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC lifted its holdings in Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company's stock worth $1,293,000 after acquiring an additional 134 shares during the last quarter. DMC Group LLC lifted its holdings in Edwards Lifesciences by 4.5% in the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company's stock worth $272,000 after acquiring an additional 154 shares during the last quarter. Granite Harbor Advisors Inc. lifted its holdings in Edwards Lifesciences by 4.2% in the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company's stock worth $265,000 after acquiring an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC lifted its holdings in Edwards Lifesciences by 2.7% in the fourth quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company's stock worth $449,000 after acquiring an additional 155 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $1.58 during mid-day trading on Friday, hitting $86.43. The company's stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock's fifty day moving average price is $90.28 and its two-hundred day moving average price is $78.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. Research analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. OTR Global raised Edwards Lifesciences from a "mixed" rating to a "positive" rating in a report on Tuesday, March 26th. Stifel Nicolaus lifted their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a "hold" rating in a report on Friday. Oppenheimer lifted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a report on Monday, March 18th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating in a report on Thursday, March 7th. Finally, StockNews.com cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.33.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.